TOP > 外国特許検索 > Bis(arylmethylidene)acetone compound, anti-cancer agent, carcinogenesis-preventive agent, inhibitor of expression of Ki-Ras, ErbB2, c-Myc and Cycline D1, β-catenin-degrading agent, and p53 expression enhancer

Bis(arylmethylidene)acetone compound, anti-cancer agent, carcinogenesis-preventive agent, inhibitor of expression of Ki-Ras, ErbB2, c-Myc and Cycline D1, β-catenin-degrading agent, and p53 expression enhancer UPDATE

外国特許コード F130007253
掲載日 2013年4月2日
出願国 アメリカ合衆国
出願番号 99384006
公報番号 20100152493
公報番号 8178727
出願日 平成18年6月27日(2006.6.27)
公報発行日 平成22年6月17日(2010.6.17)
公報発行日 平成24年5月15日(2012.5.15)
国際出願番号 JP2006312806
国際公開番号 WO2007000998
国際出願日 平成18年6月27日(2006.6.27)
国際公開日 平成19年1月4日(2007.1.4)
優先権データ
  • 特願2005-187394 (2005.6.27) JP
  • 2006WO-JP312806 (2006.6.27) WO
発明の名称 (英語) Bis(arylmethylidene)acetone compound, anti-cancer agent, carcinogenesis-preventive agent, inhibitor of expression of Ki-Ras, ErbB2, c-Myc and Cycline D1, β-catenin-degrading agent, and p53 expression enhancer UPDATE
発明の概要(英語) (US8178727)
It has been demanded to improve the poor solubility of curcumin to develop an anti-tumor compound capable of inhibiting the growth of various cancer cells at a low concentration.
Thus, disclosed is a novel synthetic compound, a bis(arylmethylidene)acetone, which has both of an excellent anti-tumor activity and a chemo-preventive activity.
A bis(arylmethylidene)acetone (i.e., a derivative having a curcumin skeleton) which is an anti-tumor compound and has a chemo-preventive activity is synthesized and screened.
A derivative having enhanced anti-tumor activity and chemo-preventive activity can be synthesized.
特許請求の範囲(英語) [claim1]
1. An inhibitor of Ki-Ras, ErbB2, c-Myc, or Cyclin D1 expression; a beta -catenin-degrading agent; a p53 expression enhancer; an anti-cancer agent; or a carcinogenesis chemopreventive agent, which comprises an effective amount of a bis(arylmethylidene)-acetone compound having the Formula:

(wherein R44 is a hydrogen atom or OR34, R33 and R38, which may be identical or different, are independently a member selected from the group consisting of a hydrogen atom, a halogen atom, a hydroxyl group, a nitro group, an alkoxy group, a hydroxy-alkoxy group, an alkoxyalkoxy group, an alkoxyalkoxyalkoxy group, an alkynyloxy group, and an azido-alkoxy group, or R33 may be taken together with the adjacent substituent OR32 or OR34 to form an alkylene-dioxy bridge, and/or R38 may be taken together with the adjacent substituent OR37 or OR39 to form an alkylene-dioxy bridge, and
R32, R34, R37 or R39, which may be identical or different, are independently a member selected from the group consisting of a hydrogen atom, an alkyl group, an alkynyl group, an alkoxyalkyl group, an alkoxyalkoxyalkyl group and an azido-alkyl group, or may be taken together with the adjacent substituent R33 or R38 to form the aforementioned bridge, provided that
(1) when R44 is a hydrogen atom, R32=R39=an alkyl group, and R33=R38=an hydroxyl atom or an alkoxy group, and
(2) a compound wherein: (a) R44 is OR34, R32=R39=an alkyl group, and R33=R38=a member selected from a hydrogen atom and an alkoxy group, and (b) R44 is OCH3, R32=R37=R39=CH3, and R33=R38.dbd.OH is excluded.
[claim2]
2. The inhibitor according to claim 1, wherein the bis(arylmethylidene)-acetone compound is selected from the group consisting of (1E,4E)-1,5-bis-[3,5-bis(methoxymethoxy)phenyl]penta-1,4-dien-3-one (GO-Y030, BBMMPP),
(1E,4E)-1,5-bis-(3,5-dimethoxy-4-methoxymethoxyphenyl)penta-1,4-dien-3-one (GO-Y031, BDMMMPP),
(1E,4E)-1,5-bis-(3,5-dimethoxy-4-methoxyethoxymethoxy-phenyl)penta-1,4-dien-3-one (GO-Y039),
(1E,4E)-1,5-bis-[4-(2-hydroxyethoxy)-3,5-dimethoxy-phenyl]penta-1,4-dien-3-one (GO-Y044),
(1E,4E)-1-(3,4-dimethoxyphenyl)-5-(3,4,5-trimethoxy-phenyl)penta-1,4-dien-3-one (GO-Y046),
(1E,4E)-1,5-bis-(3,5-dimethoxy-4-prop-2-ynyloxy-phenyl)pentadien-3-one (GO-Y048),
(1E,4E)-1-(3,5-dimethoxy-4-prop-2-ynyloxyphenyl)-5-(3,4,5-trimethoxyphenyl)penta-1,4-dien-3-one (GO-Y060),
(1E,4E)-1-(3,5-bis-methoxymethoxyphenyl)-5-(3,5-dimethoxy-4-prop-2-ynyloxyphenyl)penta-1,4-dien-3-one (GO-Y062),
(1E,4E)-1-(3,5-dimethoxy-4-methoxymethoxyphenyl)-5-(3,5-dimethoxy-4-prop-2-ynyloxyphenyl)penta-1,4-dien-3-one (GO-Y063),
(1E,4E)-1,5-bis-[4-(2-azidoethoxy)-3,5-dimethoxyphenyl]-penta-1,4-dien-3-one (GO-Y065),
or a salt thereof.
[claim3]
3. A bis(arylmethylidene) acetone compound having the Formula:

(wherein R44 is hydrogen or OR34, R33 and R38, which may be identical or different, are independently a member selected from the group consisting of a hydrogen atom, a halogen atom, an hydroxyl group, a nitro group, an alkoxy group, a hydroxy-alkoxy group, an alkoxyalkoxy group, an alkoxyalkoxyalkoxy group, an alkynyloxy group, and an azido-alkoxy group, or R33 may be taken together with the adjacent substituent OR32 or OR34 to form an alkylene-dioxy bridge, and/or R38 may be taken together with the adjacent substituent OR37 or OR39 to form an alkylene-dioxy bridge, and
R32, R34, R37 or R39, which may be identical or different, are independently a member selected from the group consisting of a hydrogen atom, an alkyl group, an alkynyl group, an alkoxyalkyl group, an alkoxyalkoxyalkyl group and an azido-alkyl group, or may be taken together with the adjacent substituent R33 or R38 to form the aforementioned bridge, provided that
(1) when R44 is a hydrogen atom, R32=R39=an alkyl group, and R33=R38=a hydroxyl group or an alkoxy group, and
(2) a compound wherein: (a) R44 is OR34, R32=R39=an alkyl group, and R33=R38=a member selected from a hydrogen group and an alkoxy group, and (b) R44 is OCH3, R32=R37=R39=CH3, and R33=R38 .dbd.OH is excluded.
[claim4]
4. The bis(arylmethylidene)-acetone compound according to claim 3 selected from the group consisting of (1E,4E)-1,5-bis-[3,5-bis(methoxymethoxy)phenyl]penta-1,4-dien-3-one (GO-Y030, BBMMPP),
(1E,4E)-1,5-bis-(3,5-dimethoxy-4-methoxymethoxyphenyl)penta-1,4-dien-3-one (GO-Y031, BDMMMPP),
(1E,4E)-1,5-bis-(3,5-dimethoxy-4-methoxyethoxymethoxy-phenyl)penta-1,4-dien-3-one (GO-Y039),
(1E,4E)-1,5-bis-[4-(2-hydroxyethoxy)-3,5-dimethoxy-phenyl]penta-1,4-dien-3-one (GO-Y044),
(1E,4E)-1-(3,4-dimethoxyphenyl)-5-(3,4,5-trimethoxy-phenyl)penta-1,4-dien-3-one (GO-Y046),
(1E,4E)-1,5-bis-(3,5-dimethoxy-4-prop-2-ynyloxy-phenyl)pentadien-3-one (GO-Y048),
(1E,4E)-1-(3,5-dimethoxy-4-prop-2-ynyloxyphenyl)-5-(3,4,5-trimethoxyphenyl)penta-1,4-dien-3-one (GO-Y060),
(1E,4E)-1-(3,5-bis-methoxymethoxyphenyl)-5-(3,5-dimethoxy-4-prop-2-ynyloxyphenyl)penta-1,4-dien-3-one (GO-Y062),
(1E,4E)-1-(3,5-dimethoxy-4-methoxymethoxyphenyl)-5-(3,5-dimethoxy-4-prop-2-ynyloxyphenyl)penta-1,4-dien-3-one (GO-Y063),
(1E,4E)-1,5-bis-[4-(2-azidoethoxy)-3,5-dimethoxyphenyl]-penta-1,4-dien-3-one (GO-Y065), or a salt thereof.
  • 発明者/出願人(英語)
  • SHIBATA HIROYUKI
  • IWABUCHI YOSHIHARU
  • OHORI HISATSUGU
  • YAMAKOSHI HIROYUKI
  • KAKUDO YUICHI
  • TOHOKU NATIONAL UNIVERSITY
国際特許分類(IPC)
米国特許分類/主・副
  • C07C049/223
  • C07C049/248
  • C07C049/255
  • C07C205/45
  • C07C247/04
ライセンスをご希望の方、特許の内容に興味を持たれた方は、下記「問合せ先」までご連絡ください。

PAGE TOP

close
close
close
close
close
close